Plasma Urotensin II as a Marker for Severity of Rheumatic Valve Disease

Özer, Orhan; Davutoğlu, Vedat; Ercan, Süleyman; Akçay, Murat; Sarı, İbrahim; Sucu, Murat; Çelik, Ahmet; Aksoy, Nur; Çiçek, Hülya; Al, Behçet

doi:10.1620/tjem.218.57

Cited by 8 publications

(8 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The present study was conducted on patients with rheumatic mitral or aortic regurgitation versus healthy controls for clinical examination and echocardiographic assessment. Our results were in agreement with the study by Ozer et al 13 who studied 71 patients with RVD (mean age 40 ± 12 years, 17 female patients) and 25 normal subjects (mean age 40 ± 7 years, 8 female patients). They assessed their New York Heart Association (NYHA) functional class, RVD severity and pulmonary artery pressure (PAP), and measured plasma urotensin II levels.…”

Section: Discussionsupporting

confidence: 94%

“…The present study showed that there was significant positive correlation between urotensin-II level, PAP, and LVEDD. These results were in agreement with the study by Ozer et al 13 who found that urotensin II was significantly correlated with mitral regurgitation ( r = 0.226, P = 0.02), PAP ( r = 0.320, P = 0.01), and NYHA class ( r = 0.213, P = 0.03). There was positive correlation between urotensin II levels and severity of mitral regurgitation ( r = 0.248, P = 0.01).…”

Section: Discussionsupporting

confidence: 93%

“… 1 However plasma urotensin II level in subjects with the rheumatic valve disease is not yet clear. 13 Urotensin II is mainly regarded as a cardiovascular autacoid/hormone; it might have a pathophysiological role in rheumatic valve disease.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The value of urotensin II in patients with left-sided rheumatic valvular regurgitation

Elmadbouh

Soliman

Mostafa

et al. 2017

The Egyptian Heart Journal

View full text Add to dashboard Cite

AimsRheumatic valve diseases are most common etiological valve diseases in developing countries. Urotensin II is cardiovascular autacoid/hormone and may be associated with patients of heart valve diseases. The present study was to measure plasma urotensin II concentrations in patients with left-sided rheumatic valve diseases such as mitral regurgitation (MR) and aortic regurgitation (AR), and to examine its correlation with severity of valve impairment, function (New York Heart association, NYHA) class and pulmonary artery pressure (PAP).Methods and resultsSixty patients with moderate to severe rheumatic left-sided valve regurgitation and 20 healthy controls were selected after performing the echocardiography. Plasma urotensin II level was measured in all subjects. The patients with MR and AR were significantly increased of left ventricular end diastolic dimension (LVEDD), left ventricular end systolic dimension (LVESD), left atrial diameter, PAP, but decreased of EF% versus the controls. Urotensin II level was highly significant in patients with MR (1.83 ± 0.92 ng/ml, P < 0.001) and AR (0.79 ± 0.3 ng/ml, P < 0.05) versus the controls (0.48 ± 0.13 ng/ml). Also, there was significant correlation between Urotensin II level and LVEDD (MR, r = 0.318, P = 0.03; AR, r = 0.805, P < 0.001), LVESD (MR, r = −0.271, P = 0.115; AR, r = 0.614, P = 0.001), and PAP (MR, r = 0.706, P < 0.001; AR, r = 0.129, P = 0.538).ConclusionUrotensin II was elevated in patients with rheumatic left-sided valvular regurgitation, and positively correlated with increased LVEDD (in both MR and AR), LVESD (only AR) and pulmonary artery pressure (only MR). Therefore, urotensin II level may be used as diagnostic biomarker in patients with rheumatic valvular diseases for assessment of the severity in parallel with echocardiography.

show abstract

Section: Discussionsupporting

confidence: 94%

Section: Discussionsupporting

confidence: 93%

See 1 more Smart Citation

The value of urotensin II in patients with left-sided rheumatic valvular regurgitation

Elmadbouh

Soliman

Mostafa

et al. 2017

The Egyptian Heart Journal

View full text Add to dashboard Cite

show abstract

“…In heart failure, UII plasma concentrations are not only increased but also correlate with Big endothelin-1 (Big-ET-1) and brain natriuretic peptide levels as well as with New York Heart Association functional class (43,93) and negatively correlate with left ventricular ejection fraction (43). Recent evidence suggests that UII is also a useful biomarker for diabetic retinopathy and carotid atherosclerosis in type 2 diabetes (119) and in rheumatic valve disease (93).…”

Section: Uii As a Biomarkermentioning

confidence: 99%

Role of urotensin II in health and disease

Ross

McKendy

Giaid

2010

American Journal of Physiology-Regulatory, Integrative and Comp

128

107

View full text Add to dashboard Cite

Urotensin II (UII) is an 11 amino acid cyclic peptide originally isolated from the goby fish. The amino acid sequence of UII is exceptionally conserved across most vertebrate taxa, sharing structural similarity to somatostatin. UII binds to a class of G protein-coupled receptor known as GPR14 or the urotensin receptor (UT). UII and its receptor, UT, are widely expressed throughout the cardiovascular, pulmonary, central nervous, renal, and metabolic systems. UII is generally agreed to be the most potent endogenous vasoconstrictor discovered to date. Its physiological mechanisms are similar in some ways to other potent mediators, such as endothelin-1. For example, both compounds elicit a strong vascular smooth muscle-dependent vasoconstriction via Ca 2ϩ release. UII also exerts a wide range of actions in other systems, such as proliferation of vascular smooth muscle cells, fibroblasts, and cancer cells. It also 1) enhances foam cell formation, chemotaxis of inflammatory cells, and inotropic and hypertrophic effects on heart muscle; 2) inhibits insulin release, modulates glomerular filtration, and release of catecholamines; and 3) may help regulate food intake and the sleep cycle. Elevated plasma levels of UII and increased levels of UII and UT expression have been demonstrated in numerous diseased conditions, including hypertension, atherosclerosis, heart failure, pulmonary hypertension, diabetes, renal failure, and the metabolic syndrome. Indeed, some of these reports suggest that UII is a marker of disease activity. As such, the UT receptor is emerging as a promising target for therapeutic intervention. Here, a concise review is given on the vast physiologic and pathologic roles of UII.UT receptor; somatostatin; human; experimental animals; autocrine/paracrine UROTENSIN II (UII) was initially isolated from the urophysis of the goby fish (Gillichthys mirabilis) (97). The peptide was subsequently isolated from the white sucker (Catostomus commersoni) and the carp (Cyprinus carpio). Although there were variations in the amino acid sequence near the amino terminus, in both species the UII molecule retained the COOH-terminal cyclic sequence: -Cys

show abstract

“…Many RMVD patients are children living in developing countries (Marijon et al, 2012). With the advancement of molecular medicine, efforts have been made to identify molecular markers of disease for clinical applications (Ozer et al, 2009;Banerjee et al, 2014;Leão et al, 2014). However, few RMVD biomarkers are known.…”

Section: Introductionmentioning

confidence: 99%

Identification of atrial fibrillation-associated microRNAs in left and right atria of rheumatic mitral valve disease patients

Yang

Shi

Yu³

et al. 2019

Genes Genet. Syst.

View full text Add to dashboard Cite

MicroRNA (miRNA) is associated with the development and pathology of atrial fibrillation (AF). In this study, we performed miRNA profiling of left and right atrium samples from individuals with AF-associated rheumatic mitral valve disease (RMVD) to identify miRNAs that are differentially expressed between RMVD patients with AF and RMVD with sinus rhythm (SR) as controls, as well as between left and right atrium samples from RMVD with AF patients. We performed hematoxylin and eosin staining as well as scanning and transmission electron microscopy to examine in detail any morphological and physiological changes in cardiomyocytes from RMVD patients with AF or SR. Raman spectroscopy was performed to identify molecular and structural information of left and right atrium samples from RMVD with AF and SR. We also performed miRNA array profiling to separately profile miRNA expression patterns of right and left atrium samples from three independent RMVD patients with AF and in a mixed pool of 10 RMVD patients with SR. Morphological and physiological analysis showed distinct shapes and structures of cardiomyocytes from the left and right atria of RMVD patients with AF or SR. The intensity of Raman spectroscopy of atrial tissues from RMVD patients with AF and with SR was different. miRNA profiling showed differential miRNA expression between RMVD patients with AF or SR, and between the left and right atria of RMVD patients with AF. Importantly, miRNAs showed consistent expression changes among all three patients, suggesting that these miRNAs have potential as markers for AF pathology. Our results revealed potential biomarker miRNAs for atrial fibrillation pathology in patients with RMVD. Meanwhile, our data suggested that miR-10b and miR-138-2, which were both significantly increased in the left atrium, are responsible for morphological and physiological phenotype differences between the left and right atria.

show abstract

Plasma Urotensin II as a Marker for Severity of Rheumatic Valve Disease

Cited by 8 publications

References 32 publications

The value of urotensin II in patients with left-sided rheumatic valvular regurgitation

The value of urotensin II in patients with left-sided rheumatic valvular regurgitation

Role of urotensin II in health and disease

Identification of atrial fibrillation-associated microRNAs in left and right atria of rheumatic mitral valve disease patients

Contact Info

Product

Resources

About